#1 Clinical Trials Search in Europe

Etoposide

Etoposide is a chemotherapy drug being studied in several clinical trials for its potential in treating different types of cancer, particularly leukemia and lymphoma. This article explores how etoposide is being used in combination with other drugs or as a standalone treatment to improve outcomes for patients with challenging cancers. We’ll look at its applications in stem cell transplantation and for relapsed or resistant cancers in both children and adults.

Table of Contents

What is Etoposide?

Etoposide is a chemotherapy drug used to treat various types of cancer. It’s also known by other names such as VP-16 or VP-16,213[1]. Etoposide belongs to a class of drugs called topoisomerase inhibitors, which work by interfering with the cancer cells’ ability to divide and grow[2].

How Etoposide Works

Etoposide targets a specific protein in cancer cells called topoisomerase II. This protein is essential for cancer cells to divide and multiply. By inhibiting topoisomerase II, etoposide prevents cancer cells from growing and spreading, ultimately leading to their death[2]. Understanding how etoposide affects cancer cells helps researchers develop more effective treatment strategies and combinations with other drugs.

Conditions Treated with Etoposide

Etoposide is used to treat various types of cancer, including:

  • Small Cell Lung Cancer (SCLC): This is an aggressive form of lung cancer for which etoposide is commonly used in combination with other drugs[2][3].
  • Non-Hodgkin’s Lymphoma: A type of blood cancer affecting the lymphatic system[4].
  • Brain and Central Nervous System Tumors: Including ependymomas, which are tumors that form in the brain or spinal cord[1].
  • Acute Leukemias: Cancers of the blood and bone marrow[5].
  • Testicular Cancer: Particularly in cases of seminoma, a type of testicular cancer[6].

How Etoposide is Administered

Etoposide can be given in different ways, depending on the specific treatment plan and type of cancer:

  • Intravenous (IV) Injection: Etoposide is often given through a vein over a period of time. For example, it may be administered daily for 3-5 days as part of a treatment cycle[1][3].
  • Oral Capsules: In some cases, etoposide can be taken by mouth in capsule form. This allows for more convenient at-home treatment in certain situations[2][4].

The dosage and schedule of etoposide administration can vary based on factors such as the type of cancer, the patient’s overall health, and whether it’s being used alone or in combination with other treatments.

Etoposide in Combination Therapies

Etoposide is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

  • Etoposide + Cisplatin: This combination is frequently used in treating small cell lung cancer and other solid tumors[1][7].
  • Etoposide + Carboplatin: Another combination used in lung cancer treatment[6].
  • Etoposide + Mitoxantrone: Used in treating certain types of leukemia[8].
  • Etoposide + Cyclophosphamide + Cisplatin: A combination used in treating lymphomas and other cancers[9].

These combinations are designed to target cancer cells in multiple ways, potentially increasing the effectiveness of treatment while managing side effects.

Potential Side Effects

Like all chemotherapy drugs, etoposide can cause side effects. It’s important to discuss these with your healthcare provider. Common side effects may include:

  • Lowered blood counts (white blood cells, red blood cells, and platelets), which can increase the risk of infection, anemia, and bleeding
  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Loss of appetite
  • Mouth sores

Your healthcare team will monitor you closely for these and other potential side effects and may adjust your treatment plan as needed[7].

Ongoing Research and Clinical Trials

Researchers continue to study etoposide to improve its effectiveness and explore new applications. Some areas of ongoing research include:

  • Combination with newer drugs: Studies are looking at combining etoposide with newer targeted therapies or immunotherapies to enhance treatment outcomes[7].
  • Personalized medicine approaches: Research is exploring how genetic factors might influence a patient’s response to etoposide, potentially leading to more tailored treatment plans[2].
  • New formulations: Scientists are investigating different ways of delivering etoposide to improve its effectiveness or reduce side effects.
  • Expanded use in other cancer types: Clinical trials are exploring the use of etoposide in treating additional types of cancer or at different stages of disease[10].

These ongoing studies aim to improve treatment outcomes and quality of life for patients receiving etoposide-based therapies.

Aspect Details
Cancer Types Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin’s Lymphoma, Metastatic Breast Cancer
Patient Groups Children, Adolescents, Adults with relapsed or resistant cancers
Administration Methods Intravenous infusion, Oral capsules
Common Combinations Clofarabine, Cyclophosphamide, Fludarabine, ATG, Treosulfan, Thiotepa
Treatment Goals Improve survival rates, Increase remission rates, Prepare for stem cell transplantation
Key Outcomes Measured Event-free survival, Overall survival, Response rates, Toxicity levels
Special Applications Conditioning regimens for stem cell transplantation, Treatment for high-risk or relapsed cancers

FAQ

  • What types of cancer is etoposide being studied for in clinical trials? Etoposide is being studied for various cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and metastatic breast cancer. It's particularly being investigated for high-risk or relapsed cases of these cancers.
  • How is etoposide typically administered in these trials? Etoposide can be given intravenously or orally. In some trials, it's given intravenously over 2 hours, while in others, it's given as oral capsules daily for a certain number of days in each treatment cycle.
  • What are some common drug combinations used with etoposide in clinical trials? Etoposide is often combined with other chemotherapy drugs. Common combinations include etoposide with clofarabine and cyclophosphamide for leukemia, or with fludarabine and other drugs for stem cell transplantation conditioning.
  • What are researchers hoping to achieve with etoposide in these clinical trials? Researchers are aiming to improve survival rates, increase remission rates, and find effective treatments for patients with relapsed or resistant cancers. They're also studying the drug's effectiveness in preparing patients for stem cell transplantation.
  • What are some potential side effects of etoposide treatment? While specific side effects aren't detailed in the trial summaries, chemotherapy drugs like etoposide can cause side effects such as lowered blood counts, fatigue, and increased risk of infections. The trials are monitoring for toxicity and adverse events to ensure patient safety.

Ongoing Clinical Trials on Etoposide

  • Study on Reduced Intensity Radio-Chemotherapy for Stage IIA/B Seminoma Using Etoposide, Cisplatin, and Carboplatin for Patients with Stage IIA/B Seminoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study for Patients with Advanced Non-Small Cell Lung Cancer Worsened by Osimertinib Treatment, Using Selumetinib and Drug Combination

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands Norway Spain Sweden

  • Study on Adjuvant Treatment for Unilateral Retinoblastoma with Vincristine Sulfate and Drug Combination in Patients After Primary Eye Removal

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin versus High-Dose Chemotherapy with Paclitaxel and Drug Combination for Relapsed Germ Cell Tumors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark France Germany Ireland Italy +2

  • Study on the Effectiveness and Safety of Cisplatin, Carboplatin, Etoposide, and Durvalumab in Patients with Limited Stage Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark Germany The Netherlands Norway Sweden

  • Study on Pembrolizumab, Etoposide, and Cisplatin or Carboplatin for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Hungary Italy Poland Spain

  • Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Spain

  • Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Czechia Germany Italy Poland Slovenia

Glossary

  • Acute Lymphoblastic Leukemia (ALL): A type of cancer that affects the blood and bone marrow, causing the body to produce too many immature white blood cells called lymphoblasts.
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow that leads to the rapid growth of abnormal white blood cells that interfere with normal blood cell production.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, which can develop into new, healthy blood cells.
  • Graft-versus-Host Disease (GvHD): A potential complication of stem cell transplantation where the donor's immune cells attack the recipient's tissues.
  • Remission: A period during which cancer symptoms lessen or disappear, though the cancer may still be present in the body.
  • Relapsed Cancer: Cancer that returns after a period of improvement or remission.
  • Refractory Cancer: Cancer that does not respond to treatment or stops responding after initial improvement.
  • Total Body Irradiation (TBI): A form of radiotherapy used to prepare the body for stem cell transplantation by suppressing the immune system and killing cancer cells.
  • Antithymocyte Globulin (ATG): An antibody used to suppress the immune system, often used in stem cell transplantation to prevent rejection.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.

References

  1. https://clinicaltrials.gov/study/NCT00002876
  2. https://clinicaltrials.gov/study/NCT01064466
  3. https://clinicaltrials.gov/study/NCT06049966
  4. https://clinicaltrials.gov/study/NCT00002880
  5. https://clinicaltrials.gov/study/NCT00002912
  6. https://clinicaltrials.gov/study/NCT01887340
  7. https://clinicaltrials.gov/study/NCT01579929
  8. https://clinicaltrials.gov/study/NCT00002688
  9. https://clinicaltrials.gov/study/NCT00002488
  10. https://clinicaltrials.gov/study/NCT01294670